abbvie stock forecast 2030
Always conduct your own due diligence before investing. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. All rights reserved. The official website for the company is www.abbvie.com. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? View institutional ownership trends. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. That is a significant difference because at a forward P/E of 10x AbbVie stock looks like a solid buy opportunity, but at a P/E of 20x, when we consider the risk/challenge of Humira's LOE, prospective investors may prefer to maintain a watching brief as opposed to opening a position. I hope to see you there. Finally, AbbVie was able to raise its financial . However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. Myelofibrosis has proved to be a tricky indication for drug developers and there are no wholly satisfactory solutions on the market at present, therefore if approved I would expect Navitoclax - a drug that AbbVie has been working on for some time - to generate a couple of billion dollars in peak sales. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Please. The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska druba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacuticos S.A. de C.V., AbbVie Farmacutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S. r.l., AbbVie Investments Limited, AbbVie Investments S. r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementr GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. Having so much debt in a prevailing inflationary environment is also unattractive. Shares of ABBV stock can be purchased through any online brokerage account. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. Skyrizi has shown superiority to Humira in fields such as plaque psoriasis by a statistically significant amount, with a comparable safety profile, whilst Rinvoq has shown superiority in e.g. I have no business relationship with any company whose stock is mentioned in this article. Within the oncology division sales of Imbruvica fell 17% year-on-year. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. Forecasts shouldnt be used as a substitute for your own research. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. You should do your own research and never invest money you cannot afford to lose. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The most recent increase was . AbbVie Stock: Still A Solid Buy After Modeling Sales To 2030 What is a Good Dividend Yield? AbbVie projected sales - immunology (my forecasts and assumptions). AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. AbbVie Stock Forecast 03-06-2023. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. AbbVie Stock: A Blue Chip You Cannot Afford To Miss, Yield 4.1% On average, they predict the company's stock price to reach $161.12 in the next year. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. The five-year dividend growth rate is just below 18%. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. Real-time analyst ratings, insider transactions, earnings data, and more. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. The surge in revenues can primarily be attributed to its Allergan. ABBV - Abbvie Inc Forecast - CNNMoney.com - CNN Business In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. To see all exchange delays and terms of use please see Barchart's disclaimer. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. Allergan was a troubled company in many ways, but there is no doubting the strength of its products and pipeline. contact@marketbeat.com It now expects full-year profit in the range of $13.92-$14.12 a share. Disclaimer. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Richard A. Gonzalez has an approval rating of 88% among the company's employees. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Please disable your ad-blocker and refresh. I wrote this article myself, and it expresses my own opinions. losed Joint Stock Company FinTech Solutions, Fidelity NASDAQ Composite Index Tracking Stock Fund, Abbvie stock price analysis: Past year performance, Abbvie fundamental analysis: Q1 2022 earnings, Abbvie stock forecast: Company guidance and analysts predictions. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. Kateryna Onyshchuk/iStock via Getty Images. GSK Stock Forecast 2023 - 2025 - 2030 | StockForecast.com 67.71% of the stock of AbbVie is held by institutions. To summarize, Humira may be going off-patent, but is more than capable of delivering double-digit billion revenues for another 3-4 years, and even in 2030, it could be amongst the top 20 best-selling drugs worldwide. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Please. All rights reserved. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. The company reported its first revenue for Botox competitor Daxxify. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. As such, forecasting stock prices is more of an art than a science. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. How often does AbbVie pay dividends? Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. The dividend payout ratio is 89.56%. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. ABBV has several positive factors pushing its price performance. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. See what's happening in the market right now with MarketBeat's real-time news feed. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. View which stocks are hot on social media with MarketBeat's trending stocks report. Date. How do I arrive at my share price target? AbbVie: Modelling The Post Humira Bull Case To 2030 (ABBV) Most stock quote data provided by BATS. Sign in to your free account to enjoy all that MarketBeat has to offer. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. AbbVie saw a increase in short interest in February. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. ABBV currently yields 4.1% and has raised its dividend every year since 2013. Factset: FactSet Research Systems Inc.2019. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. What is the dividend yield for AbbVie? What guidance has AbbVie issued on next quarter's earnings? Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Over the years, AbbView Inc. has made numerous acquisitions. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Teliso V is an antibody drug conjugate and a c-Met inhibitor. I have been maintaining a revenue forecasting table for AbbVie's products which I have amended based on Q2'22 and H1'22 results, and the slightly downgraded guidance issued for 2022 - management now expects adjusted earnings per share ("EPS") of $13.78 - $13.98, representing growth of 17% at the midpoint. (my table and forecasts). It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Capital Com is an execution-only service provider. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. AbbVie (ABBV) Stock Forecast & Price Target - TipRanks As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. I wrote this article myself, and it expresses my own opinions. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. This year is off to a strong start. Skyrizi - which inhibits the activities of IL-23 - a naturally occurring cytokine that is involved in inflammatory and immune responses - and Rinvoq - a member of the janus kinase inhibitor drug class - fit this profile. The pharma industry witnessed solid growth amid the pandemic. I am not receiving compensation for it (other than from Seeking Alpha). Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock. American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. Only 0.08% of the stock of AbbVie is held by insiders. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). The average price target represents a 6.33% change from the last price of $153.90. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. The company didn't offer a . AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. (AbbVie data). Receive regular, detailed analysis focused on biotech and healthcare stocks. CNN Sans & 2016 Cable News Network. Build a CFD portfolio with your favourite companies. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. Is this happening to you frequently? AbbVie Inc. (ABBV) Stock Forecast & Price Targets - Stock Analysis Gene therapies have been a long time coming, having first been popularized in the early noughties. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. 1 dividend stock for a LIFETIME of income. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. AbbVie has 5 focus areas for its research and products. On average, analysts rate AbbVie stock as a buy. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. AbbVie stock is one of the most well-known pharmaceutical companies. What is Richard A. Gonzalez's approval rating as AbbVie's CEO? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. And never invest or trade money you cannot afford to lose. It should be noted however that, with ~$12bn near-term debt falling due, and long-term debt of ~$61bn - most of it due to the $66bn acquisition of Allergan, completed in 2020, AbbVie has some hefty interest expense payments to make - $15bn between 2022 and 2027, I estimate, and the level of debt makes it tough for the company to invest in M&A deals. I'm on twitter @edmundingham. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt.